Novartis presents new data in breast and prostate cancer at ESMO
August 30, 2022 01:15 ET
|
Novartis Pharma AG
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® Data from VISION study reporting...
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
August 25, 2022 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse der...
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
August 25, 2022 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1...
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
July 19, 2022 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1 (-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec...
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022
July 19, 2022 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im zweiten Quartal um +5% kWk1 (–1% USD) Innovative Medicines (IM) steigerte den Umsatz um +5% kWk (–1% USD); starke Performance der wichtigsten...
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
July 19, 2022 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%...
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
June 30, 2022 04:00 ET
|
Novartis Pharma AG
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal...
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
June 22, 2022 19:12 ET
|
Novartis Pharma AG
Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with...
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
June 06, 2022 08:00 ET
|
Novartis Pharma AG
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in...
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
May 20, 2022 08:34 ET
|
Novartis Pharma AG
Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these...